

## Human Genome Sciences

[View the current Human Genome Sciences Page on BioPortfolio.com](http://www.bioportfolio.com/bi corporate/24010-Human+Genome+Sciences.html)

(<http://www.bioportfolio.com/bi corporate/24010-Human+Genome+Sciences.html>)

### Contact Details:

**14200 Shady Grove Road  
Rockville  
Maryland  
20850  
United States of America**

Tel: (301) 309-8504

Fax: (301) 309-8512

Email:

The mission of Human Genome Sciences is to discover, develop, manufacture and market innovative drugs that serve patients with unmet medical needs, with a primary focus on protein and antibody drugs. Clinical Development Pipeline

The HGS clinical development pipeline includes drugs to treat hepatitis C, lupus, anthrax disease, cancer, rheumatoid arthritis and HIV/AIDS. The Company's primary focus is rapid progress toward the commercialization of our two lead products, Albuferon for hepatitis C, and LymphoStat-B for lupus. We have entered into collaboration agreements with two of the world's leading pharmaceutical companies for the co-development and co-commercialization of these products. Our Albuferon collaborator is Novartis. Our LymphoStat-B collaborator is GlaxoSmithKline. We expect both Albuferon and LymphoStat-B to advance to Phase 3 clinical trials in 2006.

### Recent Publications by Human Genome Sciences:



- [Tumor necrosis factor-related apoptosis-inducing ligand \(TRAIL\) receptor-1 and receptor-2 agonists for cancer therapy.](#)  
*Importance of the field: Agents that activate the TNF-related...*28th October, 2009  
Human Genome Sciences, 14200 Shady Grove Road, Rockville, MD, 20850, USA- Expert Opin Biol Ther. 2009 Oct 27. ([DOI Direct Link](#))
- [Raxibacumab for the treatment of inhalational anthrax.](#)  
*BACKGROUND: Inhalational anthrax caused by Bacillus anthracis is...*21st July, 2009  
Human Genome Sciences,- N Engl J Med. 2009 Jul 9;361(2):135-44. ([DOI Direct Link](#))
- [Mapatumumab and lexatumumab induce apoptosis in TRAIL-R1 and TRAIL-R2 antibody-resistant NSCLC cell lines when treated in combination with bortezomib.](#)  
*Mapatumumab and lexatumumab are fully human monoclonal antibodies that...*25th March, 2009

- Oncology Research Department, Human Genome Sciences, Inc., Rockville, MD- Mol Cancer Ther. 2009 Feb;8(2):292-302. Epub 2009 Jan 27. ([DOI Direct Link](#))
- [High cell density and productivity culture of Chinese hamster ovary cells in a fluidized bed bioreactor.](#)  
A recombinant Chinese hamster ovary clone was cultivated in a 2L Cytopilot...13th November, 2008  
Human Genome Sciences, Inc., 9410 Key West Ave., Rockville, MD, 20850,- Cytotechnology. 1999 May;29(3):215-20. ([DOI Direct Link](#))
  - [Potent in vitro activity of the albumin fusion type 1 interferons \(albumin-interferon-alpha and albumin-interferon-beta\) against RNA viral agents of bioterrorism and the severe acute respiratory syndrome \(SARS\) virus.](#)  
*BACKGROUND: The type 1 interferons (INF-alpha and INF-beta) are potent...*13th August, 2008  
Human Genome Sciences, Inc., Rockville, MD 20850, USA.- Chemotherapy. 2008;54(3):176-80. Epub 2008 Jun 18. ([DOI Direct Link](#))
  - [High-level production of a monoclonal antibody in murine myeloma cells by perfusion culture using a gravity settler.](#)  
A perfusion system is described for the production of a human monoclonal...11th June, 2008  
Department of Process Development, Human Genome Sciences Inc., 14200 Shady- Biotechnol Prog. 2007 Jan-Feb;23(1):225-31. ([DOI Direct Link](#))
  - [Trail receptors: targets for cancer therapy.](#)  
A human tumor cell's ability to avoid the normal regulatory mechanisms of...14th May, 2008  
Human Genome Sciences, Oncology Research Department, Rockville, MD 20850,- Adv Exp Med Biol. 2008;615:127-58. ([DOI Direct Link](#))
  - [Inference of haplotype effects in case-control studies using unphased genotype and environmental data.](#)  
A retrospective likelihood-based approach was proposed to test and...14th May, 2008  
Department of Biostatistics, Human Genome Sciences, Inc., 14200 Shady- Biom J. 2008 Apr;50(2):270-82. ([DOI Direct Link](#))
  - [Albinterferon alpha-2b: a genetic fusion protein for the treatment of chronic hepatitis C.](#)  
Treatment regimens based on the use of interferon-alpha (IFN-alpha) remain...23rd February, 2008  
Human Genome Sciences, Inc., 14200 Shady Grove Road, Rockville, Maryland- Nat Biotechnol. 2007 Dec;25(12):1411-9. ([DOI Direct Link](#))
  - [Lyophilization cycle development for a high-concentration monoclonal antibody formulation lacking a crystalline bulking agent.](#)  
An efficient freeze-dry cycle was developed for a high concentration...21st July, 2007  
Human Genome Sciences, Inc., Department of Pharmaceutical Sciences, 14200- J Pharm Sci. 2007 Jun;96(6):1598-608. ([DOI Direct Link](#))
  - [Chronic administration of belimumab, a BLYS antagonist, decreases tissue and peripheral blood B-lymphocyte populations in cynomolgus monkeys: pharmacokinetic, pharmacodynamic, and toxicologic effects.](#)  
The tolerability, pharmacodynamic effects, and pharmacokinetics of...10th August, 2006  
Human Genome Sciences, Inc., Rockville, Maryland 20850, USA.- Toxicol Sci. 2006 Jun;91(2):586-99. Epub 2006 Mar 3. ([DOI Direct Link](#))
  - [A phase 1 study of PAMAb, a fully human monoclonal antibody against Bacillus anthracis protective antigen, in healthy volunteers.](#)  
*BACKGROUND: Inhibition of the binding of Bacillus anthracis protective...*28th April, 2006  
Human Genome Sciences, Rockville,- Clin Infect Dis. 2005 Jul 1;41(1):12-20. Epub 2005 May 24. ([DOI Direct Link](#))
  - [Osteostat/tumor necrosis factor superfamily 18 inhibits osteoclastogenesis and is selectively expressed by vascular endothelial cells.](#)  
Vascular endothelial cells (EC) participate in the process of bone...4th February, 2006  
Human Genome Sciences, Inc., Rockville, Maryland 20850, USA.- Endocrinology. 2006 Jan;147(1):70-8. Epub 2005 Sep 22. ([DOI Direct Link](#))
  - [Growing cholesterol-dependent NS0 myeloma cell line in the wave bioreactor system: overcoming cholesterol-polymer interaction by using pretreated polymer or inert fluorinated ethylene propylene.](#)

**Press Releases on Human Genome Sciences:**

<p><a href="#">Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor</a></p>	<p>27th November, 2009</p>		<p><i>NEUILLY-SUR-SEINE, France, November 27 /PRNewswire/ -- Team Garmin-Slipstream, the elite American professional cycling team dedicated to ethical sporting and developing the next generation of cycling</i></p>
<p><a href="#">"As an Industry, We've Been too Focused on Regulatory Approval," Says Solvay Pharmaceuticals Eric Rambeaux at the Pharma Marketing Summit.</a></p>	<p>26th November, 2009</p>		<p><i>LONDON, November 26 /PRNewswire/ -- Rambeaux joined a host of other industry leaders at eyeforpharma's 9th annual Pharma Marketing Summit 2009 conference in Berlin, where several key themes</i></p>
<p><a href="#">Sentinelle Medical Launches Aegis Suite of Oncology 4D Visualization Software with PureWeb(TM) Technology</a></p>	<p>25th November, 2009</p>	<p>Sentinelle Medical Inc.</p>	<p><i>TORONTO, Nov. 25 /PRNewswire/ - Sentinelle Medical Inc., a leading manufacturer of breast MRI coils and advanced visualization software launches a suite of new leading edge clinical applications on</i></p>
<p><a href="#">Sentinelle Medical Inc. Introduces Aegis(TM) Web Powered By Calgary Scientific's PureWeb Technology</a></p>	<p>25th November, 2009</p>	<p>Sentinelle Medical Inc.</p>	<p><i>TORONTO and CALGARY, Nov. 25 /PRNewswire/ - Sentinelle Medical Inc., a leading manufacturer of Magnetic Resonance Imaging (MRI) coils and software and Calgary Scientific Inc., a leading provider of</i></p>
<p><a href="#">The Lupus Foundation of America Hosts Special Webinar to Discuss BENLYSTA(TM) Results</a></p>	<p>25th November, 2009</p>	<p>Lupus Foundation of America</p>	<p><i>WHAT: The Lupus Foundation of America (LFA) invites those living with lupus to a special Webinar with LFA's Medical Director, Dr. Joan Merrill. Human Genome Sciences (HGSI) and GlaxoSmithKline</i></p>

- [Efficacy and safety of albinterferon alfa-2b in combination with ribavirin in treatment-naive patients with ch](#)  
*National AIDS Treatment Advocacy Project: Nov 22 2009 6:25AM Matching: human genome sciences*
- [Scientists uncover complete genetic code of corn](#)  
*Oman Tribune: Nov 20 2009 11:29PM Matching: human genome sciences*
- [University of Minnesota Plant Scientist Uncovers Clues to Yield-boosting Quirks of Corn Genome](#)  
*Biobased Information Systems: Nov 20 2009 2:53PM Matching: human genome sciences*
- [Westernised diet leads to obesity via gut microbes](#)  
*Irish Medical News: Nov 20 2009 6:08AM Matching: human genome sciences*
- [Researchers provide understanding to maize genome sequence](#)  
*Science Daily: Nov 20 2009 1:52AM Matching: human genome sciences*
- [HGSI's ABthrax Faces FDA Delay](#)  
*Individual.com: Nov 19 2009 3:47AM Matching: human genome sciences*
- [Human Genome Gets FDA Response Letter for Raxibacumab Biologics License Application](#)  
*TradingMarkets: Nov 19 2009 4:36AM Matching: human genome sciences*
- [Scientists uncover corn's full genetic code](#)  
*Yahoo! Malaysia: Nov 19 2009 10:53PM Matching: human genome sciences*
- [Scientists uncover corn's full genetic code](#)  
*Yahoo! UK and Ireland: Nov 19 2009 10:27PM Matching: human genome sciences*
- [Scientists uncover corn's full genetic code](#)  
*Bangkok Post: Nov 19 2009 8:45PM Matching: human genome sciences*
- [Scientists uncover corn's full genetic code](#)  
*Sydney Morning Herald: Nov 19 2009 8:10PM Matching: human genome sciences*
- [Scientists uncover corn's full genetic code](#)  
*AFP via Yahoo!: Nov 19 2009 7:18PM Matching: human genome sciences*
- [Research and Markets: Hepatitis C Virus and Therapeutics Report - A Global Update of Market...](#)  
*Forbes.com: Nov 19 2009 5:41PM Matching: human genome sciences*
- [Lightning Round OT: Anheuser-Busch, Human Genome Sciences and More](#)  
*CNBC: Nov 19 2009 1:00AM Matching: human genome sciences*
- [ISU's Plant Sciences Institute researchers provide understanding to maize genome sequence](#)  
*EurekAlert!: Nov 19 2009 9:23PM Matching: human genome sciences*

**Human Genome Sciences Clinical Trials:**



- [A Study of Albuferon With Ribavirin in Interferon Alfa Naive Subjects With Chronic Hepatitis C Genotype 2 or 3](#)





## Human Genome Sciences Patents:

- 7374764- [CD33-like protein](#)
- 7425622- [Antibodies against C3a receptor](#)
- 7427492- [Polynucleotides encoding human tumor necrosis factor receptor-like2](#)
- 7429646- [Antibodies to human tumor necrosis factor receptor-like 2](#)
- 7439333- [Vascular endothelial growth factor 2](#)
- 7446169- [Human tumor necrosis factor receptor-like 2](#)
- 7446176- [12 human secreted proteins](#)
- 7452538- [Death domain containing receptor 4 antibodies and methods](#)
- 7459531- [50 Human secreted proteins](#)
- 7465707- [Methods of treatment with TR10 polypeptides](#)
- 7470510- [Methods for diagnosing cancer and determining a susceptibility for developing cancer](#)
- 7419662- [Methods of making chemokine alpha 3 antibodies](#)
- 7416855- [Immunoassay methods for detecting interleukin-1 .beta. converting enzyme like apoptosis protease-3](#)
- 7411051- [Antibodies to HDPPA04 polypeptide](#)
- 7375192- [Antibodies that specifically bind to chemokine beta-4](#)
- 7381800- [Antibodies to HBIMF63 polypeptide](#)
- 7390637- [Keratinocyte derived interferon](#)
- 7390880- [Soluble interleukin-1 receptor accessory molecule](#)
- 7393650- [Method of producing an antibody to G-protein parathyroid hormone receptor HLTDG74](#)
- 7393832- [Extracellular/epidermal growth factor like protein](#)
- 7393934- [Human G-protein chemokine receptor \(CCR5\) HDGNR10](#)
- 7393943- [Polynucleotides encoding a human chemotactic cytokine I](#)
- 7402312- [Antibodies to vascular endothelial growth factor 2 \(VEGF-2\)](#)
- 7405059- [Modified Shine-Dalgarno sequences and methods of uses thereof](#)
- 7476384- [Death domain containing receptor 4 antibody and methods](#)
- 7482013- [Albumin fusion proteins](#)
- 7521424- [Albumin fusion proteins](#)
- 7524501- [Methods of treating an injury to, or disorder of, the eye involving photoreceptor proliferation by administering VEGF2 antibodies](#)
- 7534428- [Antibodies to tumor necrosis factor receptors 6.alpha. and 6.beta.](#)
- 7541441- [Antibodies that specifically bind to TL5](#)
- 7569384- [Albumin fusion proteins](#)
- 7576189- [Antibodies to human vascular endothelial growth factor 2 and methods of using the same](#)
- 7592010- [Albumin fusion proteins](#)
- 7595038- [Methods of treatment using antibodies to follistatin-3](#)
- 7597886- [Tumor necrosis factor-gamma](#)
- 7601351- [Antibodies against protective antigen](#)
- 7514081- [Methods of inhibiting an immune response with anti-human endokine alpha antibodies](#)
- 7514079- [Antibodies that specifically bind to neurokinin B](#)
- 7511017- [Methods of treatment with TNFR5](#)
- 7482326- [Endothelial-monocyte activating polypeptide III](#)
- 7482442- [HEMCM42 nucleic acids](#)
- 7485459- [Human neuronal attachment factor-1 antibodies](#)

- 7495084- [Antibodies to T1 receptor-like ligand II](#)
- 7498027- [Methods of treatment using human tumor necrosis factor receptor TR17 antibodies](#)
- 7498417- [Antibodies to vascular endothelial growth factor 2 and methods of using same](#)
- 7501123- [Human G-protein chemokine receptor \(CCR5\) HDGNR10](#)
- 7504105- [Treatment using antibodies to cytokine receptor common gamma chain like](#)
- 7507413- [Albumin fusion proteins](#)
- 7507414- [Albumin fusion proteins](#)
- 7605236- [Antibodies that immunospecifically bind to B lymphocyte stimulator protein](#)

## BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

\*\*\*

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

